ERBB2 and breast carcinoma: Breast cancer cells with EMT-associated CSC features (CD44high, CD24low) have been reported to remain after neoadjuvant chemotherapy and HER2 pharmacological inhibition, suggesting that they encode resistance (Li et al., 2008; Blick et al., 2010).